Table 1.
Clinical trials investigating systemic treatment activity in angiosarcoma.
| Investigational Agent | Targeted Population | AS Specific | Single or Combo | N | Start Date | Expected Completion Date | Phase | NCT Identifier/EudraCT Number |
|---|---|---|---|---|---|---|---|---|
| Pazopanib | AS | Yes | Single | 30 | Nov 2011 | Jan 2019 | II | NCT01462630 |
| Regorafenib | AS | Yes | Single | 31 | Jun 2014 | Oct 2019 | II | NCT02048722 |
| Propranolol + metronomic cyclophosphamide | AS | Yes | Combo | 24 | Jan 2016 | Not provided | I/II | 2015-005177-21 |
| Oraxol (oral paclitaxel + HM30181) | AS, cutaneous | Yes | Single | 43 | Dec 2018 | Dec 2020 | I/II | NCT03544567/2019-002085-13 |
| Paclitaxel and avelumab | AS, metastatic | Yes | Combo | 32 | Jun 2018 | Nov 2022 | II | NCT03512834 |
| T-VEC | AS, skin | Yes | Single | 4 | Arp 2019 | May 2021 | II | NCT03921073 |
| Propranolol | AS, cutaneous and breast | Yes | Single | 14 | Dec 2019 | Dec 2021 | II | NCT04518124 |
| Paclitaxel + radiotherapy | AS, cutaneous | Yes | Combo | 19 | May 2019 | Dec 2021 | I/II | NCT03921008 |
| Paclitaxel + nivolumab Cabozantinib + nivolumab * |
AS of skin, radiation-associated skin, and visceral | Yes | Combo | 90 | Sep 2020 | Sep 2023 | II | NCT04339738 |
| AGN2034 + AGEN 1884 | AS | Yes | Combo | 55 | Oct 2020 | Oct 2021 | II | NCT01042379 |
| Doxorubicin + dexrazoxane | STS, including AS | No | Combo | 73 | Feb 2016 | Oct 2023 | II | NCT02584309 |
| Nivolumab + ipilimumab | Rare cancers, including AS | No | Combo | 818 | Jan 2017 | Aug 2021 | II | NCT02834013 |
| T-VEC + pembrolizumab | STS, including AS | No | Combo | 60 | Mar 2017 | Mar 2021 | II | NCT03069378 |
| Sunitinib + nivolumab | STS and bone sarcoma, including AS | No | Combo | 270 | Mar 2017 | Sep 2022 | I/II | NCT03277924/2016-004040-10 |
| Ribociclib and doxorubicin | STS, including AS | No | Combo | 16 | Mar 2017 | Oct 2019 | I | NCT03009201 |
| L19TNF + doxorubicin vs. doxorubicin | STS, including AS | No | Combo | 102 | July 2017 | Not provided | III | 2016-003239-38 |
| Durvalumab + tremelimumab | Sarcoma, including AS | No | Combo | 62 | Aug 2017 | Aug 2020 | II | NCT02815995 |
| RP1 +/− pembrolizumab | Solid tumor, including AS | No | Combo | 293 | Aug 2017 | Not provided | I/II | 2016-004548-12 |
| Durvalumab + trememlimumab vs. doxorubicin | STS, including AS | No | Combo | 100 | Oct 2017 | Not provided | II | 2016-004750-15 |
| Eribulin | AS and EHE | No | Single | 16 | Jan 2018 | May 2021 | II | NCT03331250 |
| Atezolizumab + radiotherapy | STS, including AS | No | Combo | 69 | Feb 2018 | Not provided | II | 2016-005019-42 |
| SPM-011 + Boron Neutron Capture Therapy | AS and melanoma | No | Combo | 9 | Nov 2019 | Dec 2021 | NA | NCT04293289 |
| Cobimetinib + atezolizumab | STS, including AS | No | Combo | 80 | Oct 2019 | Not provided | I/II | 2019-000987-80 |
(last accessed 2020/10/30 from https://www.clinicaltrials.gov and https://www.clinicaltrialsregister.eu/. Keywords: angiosarcoma; recruitment status included “not yet recruiting”, “recruiting”, and “active, not recruiting.” for ClinicalTrials.gov and “Ongoing” for EU Clinical Trial Register). AS: angiosarcoma, EHE: epithelioid hemangioendothelioma, STS: soft tissue sarcoma, T-VEC: tamilogene laherparepvec.* The cabozantinib plus nivolumab arm enrolls patients who are refractory to paclitaxel.